Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Topix" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Topix for you to read. Along with our medical data and news we also list Topix Clinical Trials, which are updated daily. BioPortfolio also has a large database of Topix Companies for you to search.
Shares of Impax Laboratories, Inc. rose 3.8% during mid-day trading on Friday . The company traded as high as $25.70 and last traded at $22.90.
New England Research & Management Inc. boosted its holdings in Bristol-Myers Squibb Company by 2.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,892 shares of the biopharmaceutical company's stock after purchasing an additional 575 shares during the quarter.
Rafferty Asset Management LLC lifted its holdings in Mylan N.V. by 34.8% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 51,420 shares of the company's stock after buying an additional 13,287 shares during the period.
In a new effort to tackle the deadly opioid addiction crisis in the US, pharmacy giant CVS announced on Friday it will limit opioid prescriptions to seven days for certain conditions. This restriction will apply to patients who are new to pain therapy.
GSK packages of Alli on display, with the drug having been manufactured at an Aiken, S.C. plant being acquired by Norwalk, Conn.-based Avara Pharmaceuticals for future use as an outsourced drug production and packaging facility in a deal announced Sept. 21, 2017.
Shares of Pharmerica Corporation have earned an average rating of "Hold" from the seven research firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a buy recommendation to the company.
Mylan NL CEO Heather Bresch holds EpiPens during a House Oversight and Government Reform Committee hearing on the Rising Price of EpiPens at the Capitol in Washington The drugmaker Mylan was founded in West Virginia and maintains its world headquarters in Pennsylvania, but for tax purposes it's been a Dutch company since 2015. This little bit of geographical magic was made possible through a c...
Gilead Sciences, Inc. is already one of the most profitable companies on the planet, but a readout expected in the near future could be a big step toward addressing one of the largest unmet needs in medicine. Here's a rundown of upcoming events that will alter perceptions of their candidates' potential in the days and weeks ahead.
Thursday was a down day for the stock market, but major benchmarks managed to limit their losses to modest amounts of less than half a percent. Investors looked at a wide variety of different factors, including a decline in weekly unemployment claims, new U.S. sanctions against North Korea, and the rising belief that the Federal Reserve will go forward with planned interest rate increases in Decem...
BioCryst Pharmaceuticals, Inc. a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for RAPIVAB , an intravenous neuraminidase inhibitor, extending its availability for the treatment of acute uncomplicated influenza to pedia...
Impax Laboratories Inc. is in talks to combine with rival Amneal Pharmaceuticals LLC as the companies seek to build strength in a challenging market for generic-drug makers. Impax and closely held Amneal are in talks that could yield a transaction next month, assuming they don't fall apart, according to people familiar with the matter.
Impax Laboratories Inc is in talks to merge with Amneal Pharmaceuticals LLC, the Wall Street Journal reported on Thursday, citing people familiar with the matter. Impax and privately held Amneal are in talks that could yield a transaction next month, according to the WSJ report.
Impax's shares soar after the Wall Street Journal reported that the drug maker is in merger discussions with Amneal Pharmaceuticals. Shares of Impax Laboratories Inc. soared 13.2% to $24.40 in afternoon trading on Thursday, Sept.
The morning after Maria: Puerto Rico could be without power for MONTHS after 'historic' 155 mph hurricane sparked landslides and flash flooding across the island killing at least one - and the megastorm may STRENGTHEN in the coming days Johnson & Johnson heiress caught on camera 'losing her temper and trying to kick her horse in the stomach' at Hampton Classic Horse Show Off-du...
The project is primarily aimed at demonstrating compliance with the Drug Supply Chain Security Act , utilizing innovative capabilities found with blockchain technology to track and trace prescription medicines. The project seeks to demonstrate the ability to prevent counterfeit medicines from entering the supply chain.
Porsche creates its first ever superyacht complete with spa pool and carbon fibre furniture Johnson & Johnson heiress caught on camera 'losing her temper and trying to kick her horse in the stomach' at Hampton Classic Horse Show Brother and sister who unwittingly had a child from an incestuous relationship after being raised in separate foster homes win their legal fight to be recogniz...
Makers of generic AIDS drugs will start churning out millions of pills for Africa containing a state-of-the-art medicine widely used in rich countries, after securing a multi-million dollar guarantee that caps prices at just $75 per patient a year. Global health experts hope the deal will help address two looming problems in the HIV epidemic - the rising threat of resistance developing to standard...
FRANKFURT: European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma. In May, Bavencio was approved by the U.S. Food and Drug Administration to treat bladder cancer and in March to treat Merkel cell carcinoma.
Are you looking to invest in companies with a good shot at growing even faster than the U.S. technology giants that have been performing so well? Michael Santoli pointed out in this CNBC article that the S&P 500 Life Sciences Tools and Services subsector has greatly outperformed the broader market this year. Following his lead, we have taken a deeper dive to highlight more of the growth leader...
Shares of Johnson & Johnson have received a consensus recommendation of "Hold" from the twenty-one ratings firms that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and eight have assigned a buy recommendation to the company.
They now have an "underperform" rating on the stock. 9/18/2017 - Teva Pharmaceutical Industries Limited had its "hold" rating reaffirmed by analysts at Cantor Fitzgerald.
Fiera Capital Corp lessened its holdings in shares of McKesson Corporation by 13.9% in the second quarter, according to its most recent filing with the SEC. The firm owned 5,171 shares of the company's stock after selling 835 shares during the period.
Two of the world's largest drugmakers are heading to court over a blockbuster arthritis treatment. Pfizer on Wednesday filed a complaint against Johnson & Johnson, claiming the world's largest pharmaceutical company was taking anticompetitive steps to block the sale of a drug called Inflectra.
New York State Common Retirement Fund decreased its holdings in shares of Cardinal Health, Inc. by 2.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,010,887 shares of the company's stock after selling 22,721 shares during the period.
Alnylam Pharmaceuticals Inc's drug to treat a rare genetic disease cleared a key study, moving the company closer to filing a marketing application for the drug, which is part of a new class of medicines that block disease-causing proteins. The company's shares soared as much as 38.4 percent to hit a 21-month high in morning trading on Wednesday.